SAGE-718
SAGE-718.svg
Legal status
Legal status
  • Investigational
Identifiers
  • (3S,8R,9S,10R,13R,14S,17R)-3,13-Dimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
CAS Number
PubChem CID
Chemical and physical data
FormulaC26H41F3O2
Molar mass442.607 g·mol−1

SAGE-718 is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment.[1] It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition.[2] SAGE-718 is an analog of the neurosteroid 24S-hydroxycholesterol.[2]

As of 2022, SAGE-718 is in Phase II clinical trials[2] for Alzheimer's disease,[3][4][5] Parkinson's disease, and Huntington's disease.[6][7]

References

  1. ^ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (July 2022). "SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment". Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.2c00313. PMID 35785990. S2CID 250250073.
  2. ^ a b c "SAGE-718". ALZFORUM.
  3. ^ Shapiro L. "#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's". BioNews, Inc.
  4. ^ "SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study" (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
  5. ^ Castañeda R (16 November 2021). "Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion". Clinical Trials Arena.
  6. ^ "Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718". Huntington's Disease Society of America.
  7. ^ Wexler M (21 September 2021). "SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy". BioNews, Inc.